[go: up one dir, main page]

MX9203444A - Medicamentos. - Google Patents

Medicamentos.

Info

Publication number
MX9203444A
MX9203444A MX9203444A MX9203444A MX9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A MX 9203444 A MX9203444 A MX 9203444A
Authority
MX
Mexico
Prior art keywords
medicines
agonist
medicament
manufacture
indicated
Prior art date
Application number
MX9203444A
Other languages
English (en)
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203444(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9203444A publication Critical patent/MX9203444A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una sal fisiológicamente aceptable de los mismos, en la manufactura de un medicamento para el tratamiento de una condición en donde se indica un agonista similar a 5-HT1, por ejemplo migraña.
MX9203444A 1991-06-26 1992-06-26 Medicamentos. MX9203444A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Publications (1)

Publication Number Publication Date
MX9203444A true MX9203444A (es) 1993-12-01

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203444A MX9203444A (es) 1991-06-26 1992-06-26 Medicamentos.

Country Status (34)

Country Link
US (2) US5464864A (es)
EP (1) EP0591280B1 (es)
JP (1) JP3261502B2 (es)
KR (1) KR100251571B1 (es)
CN (1) CN1034072C (es)
AP (1) AP344A (es)
AT (1) ATE170746T1 (es)
BR (2) BR9206237A (es)
CA (1) CA2113726C (es)
CZ (3) CZ282061B6 (es)
DE (2) DE10299042I2 (es)
DK (1) DK0591280T3 (es)
FI (1) FI103967B1 (es)
GB (1) GB9113802D0 (es)
HU (1) HU218907B (es)
IE (1) IE922062A1 (es)
IL (4) IL117104A (es)
LU (1) LU90939I2 (es)
MA (1) MA22563A1 (es)
MX (1) MX9203444A (es)
NL (1) NL300103I2 (es)
NO (2) NO304774B1 (es)
NZ (1) NZ243288A (es)
PL (3) PL171034B1 (es)
PT (1) PT100620B (es)
RU (1) RU2137474C1 (es)
SA (1) SA92130141B1 (es)
SG (1) SG47877A1 (es)
SI (1) SI9200125B (es)
SK (3) SK280907B6 (es)
TW (1) TW214544B (es)
UA (1) UA41254C2 (es)
WO (1) WO1993000086A1 (es)
ZA (1) ZA924658B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
JP2005507899A (ja) * 2001-09-28 2005-03-24 エフ．ホフマン−ラ　ロシュ　アーゲー カルベジロールの疑似多形形態
EP1523486B1 (en) 2002-06-21 2007-11-07 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
US7297711B2 (en) 2002-06-21 2007-11-20 Suven Life Sciences Limited Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
BRPI0315958B8 (pt) 2002-11-28 2021-05-25 Suven Life Sciences Ltd composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
NZ540840A (en) 2002-11-28 2008-12-24 Suven Life Sciences Ltd N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
SI1581538T1 (sl) 2002-12-18 2007-08-31 Suven Life Sciences Ltd Tetraciklični 3-substituirani indoli z afiniteto za receptor serotonina
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
SI2051962T1 (sl) * 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
AU2012287120B2 (en) 2011-07-22 2017-02-23 The University Of Chicago Treatments for migraine and related disorders
EP2935280A4 (en) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc 8'-HYDROXY-DIHYDROERGOTAMINE COMPOUNDS AND COMPOSITIONS
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2025038666A2 (en) * 2023-08-13 2025-02-20 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4172834A (en) 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
AP9200403A0 (en) 1992-07-31
FI935842A7 (fi) 1993-12-23
CN1069726A (zh) 1993-03-10
CN1034072C (zh) 1997-02-19
AP344A (en) 1994-07-05
CZ286193A3 (en) 1994-07-13
IL102322A0 (en) 1993-01-14
DE69226953T2 (de) 1999-05-12
NL300103I2 (nl) 2003-02-03
SI9200125A (en) 1992-12-31
HK1014669A1 (en) 1999-09-30
NO304774B1 (no) 1999-02-15
SK280905B6 (sk) 2000-09-12
ZA924658B (en) 1993-12-24
IL117105A0 (en) 1996-06-18
IL117104A (en) 1997-09-30
FI935842A0 (fi) 1993-12-23
NZ243288A (en) 1994-09-27
AU1977592A (en) 1993-01-25
CZ150696A3 (en) 1997-06-11
DE10299042I2 (de) 2005-02-03
SG47877A1 (en) 1998-04-17
PT100620B (pt) 1999-01-29
PL169392B1 (pl) 1996-07-31
NL300103I1 (nl) 2002-12-02
BR9206237A (pt) 1995-04-11
HU218907B (hu) 2000-12-28
MA22563A1 (fr) 1992-12-31
SK280907B6 (sk) 2000-09-12
SK280906B6 (sk) 2000-09-12
NO2005011I1 (no) 2005-05-18
LU90939I2 (fr) 2002-09-24
KR100251571B1 (ko) 2000-07-01
US5464864A (en) 1995-11-07
PL171034B1 (en) 1997-02-28
NO934800L (no) 1993-12-23
IL102322A (en) 1997-09-30
UA41254C2 (uk) 2001-09-17
TW214544B (es) 1993-10-11
NO2005011I2 (no) 2008-02-11
BR1100460A (pt) 2000-07-18
SA92130141B1 (ar) 2005-12-18
HUT68961A (en) 1995-08-28
EP0591280B1 (en) 1998-09-09
DE69226953D1 (de) 1998-10-15
DK0591280T3 (da) 1999-02-15
CZ150596A3 (en) 1997-05-14
DE10299042I1 (de) 2003-02-20
IL117104A0 (en) 1996-06-18
SK131993A3 (en) 1994-06-08
CZ282327B6 (cs) 1997-06-11
CZ282083B6 (cs) 1997-05-14
WO1993000086A1 (en) 1993-01-07
ATE170746T1 (de) 1998-09-15
IE922062A1 (en) 1992-12-30
CA2113726A1 (en) 1993-01-07
US5637611A (en) 1997-06-10
IL117105A (en) 1998-01-04
CZ282061B6 (cs) 1997-05-14
AU652842B2 (en) 1994-09-08
NO934800D0 (no) 1993-12-23
CA2113726C (en) 2008-02-19
EP0591280A1 (en) 1994-04-13
PT100620A (pt) 1993-09-30
PL169410B1 (pl) 1996-07-31
FI103967B (fi) 1999-10-29
SI9200125B (en) 2001-12-31
FI103967B1 (fi) 1999-10-29
JPH06508827A (ja) 1994-10-06
RU2137474C1 (ru) 1999-09-20
GB9113802D0 (en) 1991-08-14
JP3261502B2 (ja) 2002-03-04

Similar Documents

Publication Publication Date Title
MX9203444A (es) Medicamentos.
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
ES2159591T3 (es) Composicion de liberacion controlada.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
NO20053106L (no) Oral, analgesisk doseringsform med forlenget frigivelse.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
CY1107909T1 (el) Πολυστρωματικο δισκιο περιεχον ροσιγλιταζονη
UY25544A1 (es) Forma de dosificación de nefazodona
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
CO4230093A1 (es) Derivados del indol y sus usos medicos
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ES2191942T3 (es) Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento